Comparative Pharmacology
Head-to-head clinical analysis: ASMANEX HFA versus CANDEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASMANEX HFA versus CANDEX.
ASMANEX HFA vs CANDEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mometasone furoate is a corticosteroid that exerts anti-inflammatory effects by inhibiting multiple inflammatory cell types and mediators, including eosinophils, mast cells, macrophages, and lymphocytes, and reducing the release of pro-inflammatory cytokines and chemokines.
Candesartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II, leading to vasodilation and reduced blood pressure.
2 inhalations (100 mcg each) twice daily orally, maximum 400 mcg/day.
Adults: 150 mg orally once daily
None Documented
None Documented
The terminal elimination half-life of mometasone furoate following inhalation is approximately 25 hours (range 15–40 hours), reflecting slow absorption from the lungs and prolonged systemic clearance.
Terminal elimination half-life is 20-30 hours (mean 24 hours) in adults; prolonged in hepatic impairment (up to 50 hours) and requires dose adjustment.
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver. Excretion is primarily via feces (approximately 74%) and urine (approximately 8%) as metabolites. Biliary excretion contributes to fecal elimination.
Primarily hepatic metabolism via CYP2C9, with <1% excreted unchanged in urine. Approximately 70-80% eliminated in feces as metabolites, 20-30% in urine as metabolites.
Category C
Category C
Corticosteroid, Inhaled
Topical Antifungal and Corticosteroid